Skip to Main Content

An experimental CRISPR-based treatment from Editas Medicine led to meaningful improvements in the functional vision of a single patient born with a rare, genetic disease that leads to blindness — a preliminary study outcome that Editas called encouraging but that also raises some concerns its gene-editing approach is not potent enough.

The first clinical data from Editas’ treatment, called EDIT-101, were presented Wednesday at a research meeting. One patient out of four treated with a middle dose of EDIT-101 showed meaningful improvements across several different measures of functional vision. A low dose of the treatment tested in two patients was ineffective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment